Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy

被引:92
作者
Devillier, Raynier [1 ]
Coso, Diane [1 ]
Castagna, Luca [1 ,2 ]
Rossi, Isabelle Brenot [3 ]
Anastasia, Antonella [2 ]
Chiti, Arturo [4 ]
Ivanov, Vadim [1 ]
Schiano, Jean Marc [1 ]
Santoro, Armando [2 ]
Chabannon, Christian [1 ,5 ,6 ]
Balzarotti, Monica [2 ]
Blaise, Didier [1 ,5 ,6 ]
Bouabdallah, Reda [1 ]
机构
[1] Inst J Paoli I Calmettes, Dept Hematol, Transplantat & Cell Therapy Program, F-13009 Marseille, France
[2] Ist Clin Humanitas, Humanitas Canc Ctr, Hematol Unit, Milan, Italy
[3] Inst J Paoli I Calmettes, Dept Nucl Med, F-13009 Marseille, France
[4] Ist Clin Humanitas, Humanitas Canc Ctr, Nucl Med Unit, Milan, Italy
[5] Inst J Paoli I Calmettes, INSERM, CBT 510, Ctr Invest Clin Biotherapie, F-13009 Marseille, France
[6] Univ Aix Marseille, Fac Med, Inst J Paoli I Calmettes, Marseille, France
来源
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2012年 / 97卷 / 07期
关键词
Hodgkin's lymphoma; PET; outcome; relapsed refractory; ASCT; HIGH-DOSE CHEMOTHERAPY; PROGNOSTIC-FACTORS; FDG-PET; DISEASE; MULTICENTER; FAILURE; SCORE;
D O I
10.3324/haematol.2011.056051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background High-dose chemotherapy followed by autologous stem cell transplantation is the standard treatment for relapsed and/or refractory Hodgkin's lymphoma although half of patients relapse after transplantation. Predictive factors, such as relapse within 12 months, Ann-Arbor stage at relapse, and relapse in previously irradiated fields are classically used to identify patients with poor outcome. Recently, 18-fluorodeoxyglucose positron emission tomography has emerged as a new method for providing information to predict outcome. The aim of this study was to confirm the predictive value of positron emission tomography status after salvage therapy and to compare single versus tandem autologous stem cell transplantation in patients with relapsed and/or refractory Hodgkin's lymphoma. Design and Methods We report a series of 111 consecutive patients with treatment-sensitive relapsed and/or treatment-refractory Hodgkin's lymphoma who achieved complete (positron emission tomography-negative group) or partial remission (positron emission tomography-positive group) at positron emission tomography evaluation after salvage chemotherapy and who underwent single or tandem autologous stem cell transplantation. Results Five-year overall and progression-free survival rates were 81% and 64%, respectively. There were significant differences in 5-year progression-free survival (79% versus 23%; P<0.001) and 5-year overall survival (90% versus 55%, P=0.001) between the positron emission tomography-negative and -positive groups, respectively. A complete response, as determined by positron emission tomography evaluation, after salvage therapy predicted significantly better 5-year overall survival rates in both intermediate (91% versus 50%; P=0.029) and unfavorable (89% versus 58%; P=0.026) risk subgroup analyses. In the positron emission tomography-positive subgroup, tandem transplantation improved 5-year progression-free survival from 0% (in the single transplantation group) to 43% (P=0.034). Multivariate analysis showed that positron emission tomography status (hazard ratio: 5.26 [2.57-10.73]) and tandem transplantation (hazard ratio: 0.39 [0.19-0.78]) but not risk factors at relapse (hazard ratio: 1.77 [0.80-3.92]) significantly influenced progression-free survival, while only tomography status significantly influenced overall survival (hazard ratio: 4.03 [1.38-11.75]). Conclusions In patients with relapsed/refractory Hodgkin's lymphoma responding to prior salvage therapy, positron emission tomography response at time of autologous stem cell transplantation favorably influences outcome and enables identification of patients requiring single or tandem transplantation.
引用
收藏
页码:1073 / 1079
页数:7
相关论文
共 50 条
  • [31] Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma
    Majhail, Navneet S.
    Weisdorf, Daniel J.
    Defor, Todd E.
    Miller, Jeffrey S.
    McGlave, Philip R.
    Slungaard, Arne
    Arora, Mukta
    Ramsay, Norma K. C.
    Orchard, Paul J.
    MacMillan, Margaret L.
    Burns, Linda J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (10) : 1065 - 1072
  • [32] Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy
    Filippi, Andrea Riccardo
    Botticella, Angela
    Bello, Marilena
    Botto, Barbara
    Castiglione, Anna
    Gavarotti, Paolo
    Gottardi, Daniela
    Parvis, Guido
    Bisi, Gianni
    Levis, Alessandro
    Vitolo, Umberto
    Ricardi, Umberto
    LEUKEMIA & LYMPHOMA, 2013, 54 (06) : 1183 - 1187
  • [33] Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma
    Zhang, Chen
    Deng, Jili
    Xie, Yan
    Mi, Lan
    Liu, Weiping
    Wang, Xiaopei
    Zhao, Linjun
    Song, Yuqin
    Zhu, Jun
    CANCER MEDICINE, 2023, 12 (09): : 10351 - 10362
  • [34] High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma
    Rancea, Michaela
    Monsef, Ina
    von Tresckow, Bastian
    Engert, Andreas
    Skoetz, Nicole
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (06):
  • [35] Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin's lymphoma in patients older than 50 years
    Martinez, C.
    Jorge, A. S.
    Pereira, A.
    Moreno, M.
    Nunez, J.
    Gayoso, J.
    Gonzalez-Medina, J.
    Revilla, N.
    Sampol, A.
    Domingo-Domenech, E.
    de la Cruz, F.
    Morales, A.
    Rodriguez-Salazar, M. J.
    Valiente, S.
    Perez-Ceballos, E.
    Perez de Oteyza, J.
    Garcia-Sanz, R.
    ANNALS OF HEMATOLOGY, 2017, 96 (01) : 9 - 16
  • [36] Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma
    Michal Sieniawski
    Oliver Staak
    Jan-Peter Glossmann
    Thorsten Reineke
    Helena Scheuß
    Volker Diehl
    Andreas Engert
    Andreas Josting
    Annals of Hematology, 2007, 86 : 107 - 115
  • [37] High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma
    S Akhtar
    A El Weshi
    M Rahal
    M Abdelsalam
    H Al Husseini
    I Maghfoor
    Bone Marrow Transplantation, 2010, 45 : 476 - 482
  • [38] Reassessment of risk factors and long-term results of autologous stem cell transplantation in relapsed and refractory classical Hodgkin lymphoma
    Fatobene, Giancarlo
    Gouveia Linardi, Camila da Cruz
    Moreira, Frederico
    Falcao Targueta, Gabriela Matos
    Santos, Fernanda Maria
    Velasques, Rodrigo Dolphini
    Rocha, Vanderson
    Buccheri, Valeria
    HEMATOLOGICAL ONCOLOGY, 2019, 37 (03) : 310 - 313
  • [39] The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome
    Kristina Noring
    Mattias Carlsten
    Kristina Sonnevi
    Björn Engelbrekt Wahlin
    BMC Cancer, 21
  • [40] Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma
    Sieniawski, Michal
    Staak, Oliver
    Glossmann, Jan-Peter
    Reineke, Thorsten
    Scheuss, Helena
    Diehl, Volker
    Engert, Andreas
    Josting, Andreas
    ANNALS OF HEMATOLOGY, 2007, 86 (02) : 107 - 115